TAR-200 intravesical treatment system may change the treatment landscape for high-risk NMIBC patients

On 20254 month26, Johnson & Johnson announced its ongoing 2b phaseSunRISe-1 study, focusing on evaluating the single-agent efficacy and safety of TAR-200 in patients with high-risk non-muscle-invasive bladder cancer (HR-NMIBC). This research result was widely discussed for the first time at the "Major Clinical Trials in Urology" theme session at the 2025 American Urological Association (AUA) annual meeting, which aroused great attention in the industry to this innovative treatment system.

TAR-200 is a new type of intravesical drug sustained release device that continuously releases gemcitabine in the bladder through local implantation to maintain drug concentration for a longer period of time, thereby achieving stronger anti-tumor effects. Compared with traditional chemotherapy, this method not only avoids systemic toxic and side effects, but also prolongs the remission time through local high-efficiency treatment. The implantation process of TAR-200 is simple and fast, can be performed on an outpatient basis, takes only a few minutes and does not require anesthesia, providing a viable alternative for elderly patients who are not suitable for surgery.

This study focuses onBCG patients who have failed immunotherapy and are not suitable or unwilling to undergo radical cystectomy surgeryHR-NMIBC patients. The second cohort included 85 patients with carcinoma in situ (CIS) with or without papillary tumors who received TAR-200 monotherapy. The primary endpoint of the study is complete response (CR) rate at any time point. The results showed that 82.4% of patients achieved complete remission after treatment (95% CI: 72.6%-89.8%), that is, no cancer cells were detected in the bladder. This result shows that TAR-200 has significant anti-tumor activity and brings new treatment hope to patients with refractory bladder cancer.

What is even more encouraging is that the therapeutic effect of TAR-200 also shows good durability over time. Research data shows that more than half (52.9%) patients who had a complete response remained cancer-free after one year, and the median duration of response (DOR) was 25.8 months (95%CI: 8.3months to an unestimated upper limit), and some patients have not experienced recurrence for more than two years. In addition, by month 12, 86.6% of patients had not undergone cystectomy, which is of great significance to those patients who wish to preserve their bladders.

In terms of safety, TAR-200 also showed good tolerance. In the study, 83.5%of patients experienced treatment-related adverse events (TRAE), the vast majority of which were mild urinary symptoms, such as bladder irritation or mild discomfort. Only 12.9% of patients reported grade 3 or above adverse reactions, the incidence of serious adverse events was 5.9%, and the proportion of treatment discontinuation due to adverse events was only 3.5%, and no treatment-related deaths were reported. These data show that TAR-200 not only has outstanding efficacy, but also has an acceptable safety profile.

In general, TAR-200 provides a new non-surgical treatment option for HR-NMIBC patients who have no other treatment options after BCG failure. It has outstanding performance in terms of response rate, sustained response time and bladder preservation rate. As more clinical data accumulates, TAR-200 is expected to become an important part of standard treatment in the future, especially for elderly patients who are not suitable for cystectomy, and its potential value cannot be ignored.

References:Jacob, J., et al. TAR-200 monotherapy in patients with bacillus Calmette-Guérin–unresponsive high-risk non–muscle-invasive bladder cancer carcinoma in situ: 1-year durability and patient-reported outcomes from SunRISe-1. 2025 American Urological Association Annual Meeting. April 26, 2025.